HT-1197

HT-1197 is a human urothelial carcinoma cell line established from a high-grade transitional cell carcinoma of the bladder in an adult male patient. This line was derived from a recurrent tumor after multiple surgical resections and showed aggressive clinical behavior with widespread metastases prior to the patient's death. Morphologically, HT-1197 cells exhibit epithelial features, including the presence of microvilli, tonofibrils, and desmosomes as observed under electron microscopy, indicating their urothelial epithelial origin. These cells are karyotypically distinct with identifiable marker chromosomes and demonstrate the ability to grow in soft agar, a hallmark of anchorage-independent growth, and are tumorigenic in both nude mice and immunosuppressed hamsters.

At the molecular level, HT-1197 harbors several key oncogenic mutations commonly associated with bladder cancer. It carries an activating S249C mutation in FGFR3 and an E545K mutation in PIK3CA, both of which are prevalent in the pathogenesis of urothelial bladder carcinoma. Additionally, HT-1197 has a Q61R mutation in NRAS and mutations in the TERT promoter region, suggesting enhanced proliferative capacity and telomerase activity. The TP53 status includes a c.1094A>G alteration, further implicating disruption of cell cycle control and genomic stability. Genomic profiling indicates that HT-1197 belongs to a subset of urothelial cancer cell lines marked by high genomic instability and molecular features consistent with the more aggressive, muscle-invasive subtype of bladder cancer.

37°C, 5% CO₂, humidified atmosphere.

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.